Skip to main content
NovMetaPharma Co., Ltd. logo

NovMetaPharma Co., Ltd. — Investor Relations & Filings

Ticker · 229500 ISIN · KR7229500004 KO Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2026-05-19 Regulatory Filings
Country KR South Korea
Listing KO 229500

About NovMetaPharma Co., Ltd.

http://www.novmeta.com/

NovMetaPharma Co., Ltd. is a biopharmaceutical company specializing in the research and development of first-in-class drugs with differentiated mechanisms. The company focuses on creating novel therapeutics for metabolic and fibrotic diseases, addressing significant unmet medical needs. Its main pipeline includes drug candidates for type 2 diabetes (NovDB2), obesity (NovOB), chronic kidney disease (NovRD), and fibrosis (NovFS). The company's lead assets in clinical development are Cyclo-Z and CHP. NovMetaPharma aims to develop innovative treatments by leveraging its core research teams and efficient development systems to target the root causes of these complex conditions.

Recent filings

Filing Released Lang Actions
기업설명회(IR)개최결과
Regulatory Filings Classification · 65% confidence The document is a Korean announcement of an Investor Relations (IR) meeting’s date, attendees, agenda, and confirmation that IR materials have been posted on the exchange’s system. It does not contain the actual presentation content (slides or detailed financials) but merely reports the event and where materials are available. There is no substantive financial report or dataset, nor is it a regulatory form or certification. This type of IR event notice does not fit any specific category (e.g., IP covers the actual presentation content) and thus falls into the fallback category for miscellaneous regulatory announcements.
2026-05-19 Korean
기업설명회(IR)개최
Regulatory Filings Classification · 72% confidence The document is a notice announcing the schedule, venue, and details of an upcoming corporate investor relations (IR) meeting (기업설명회). It does not contain financial results, presentation slides, earnings data, or minutes; rather it simply informs stakeholders of an event to be held. This type of announcement does not fit into specific categories like Investor Presentation (which implies the actual slide deck) or Earnings Release. Consequently, it falls under miscellaneous regulatory announcements, i.e., Regulatory Filings (RNS).
2026-04-30 Korean
특허권취득(자율공시) (고시페틴의 제조방법)
Regulatory Filings Classification · 85% confidence The document is a voluntary public disclosure (“자율공시”) by a Korean company announcing the acquisition of a patent. It does not correspond to any specific financial report category (e.g., earnings release, AGM materials, management change, ESG report, etc.). Therefore it falls under the general ‘Regulatory Filings’ fallback category.
2026-04-23 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a summary of the company’s ordinary general meeting (정기주주총회) results, detailing vote outcomes on financial statements, director elections, and other resolutions, including vote percentages and attendance. It clearly represents an official declaration of voting results from a shareholder meeting. This corresponds exactly to the ‘Declaration of Voting Results & Voting Rights Announcements’ category (DVA).
2026-03-31 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for the company 'NobuMetaPharma' (주식회사 노브메타파마) covering the fiscal years 2024 and 2025. It includes the independent auditor's opinion, financial statements (Statement of Financial Position, Comprehensive Income Statement, Statement of Changes in Equity, Cash Flow Statement), and detailed notes to the financial statements. This is a comprehensive financial audit document, not an annual report (10-K) or a simple earnings release. FY 2025
2026-03-20 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) filed by NovMetaPharma. It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, net income), and details about the external auditor. While it contains financial data, it is a regulatory disclosure of the audit report submission rather than the full annual report (10-K) or a standalone audit report document. Under the provided definitions, this fits the 'Audit Report / Information' (AR) category as it reports the results of the audit process. FY 2025
2026-03-19 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.